Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Renhe Pharmacy CoSZSE:000650 83 EBITDA Margin % is 23.08% as of Jun. 2026, which is 11% above its 10-year median of 20.74. GuruFocus rates SZSE:000650 with a GF Score™ of 83/100 and a GF Value™ of ¥5.07 (Fairly Valued). The stock has 1 warning sign investors should review. Among 959 Drug Manufacturers companies, Renhe Pharmacy Co ranks better than 65.07% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Renhe Pharmacy Co's EBITDA for the
three
months ended in Jun. 2026 was ¥222 Mil. Renhe Pharmacy Co's Revenue for the
three
months ended in Jun. 2026 was ¥962 Mil. Therefore, Renhe Pharmacy Co's EBITDA margin for the quarter that ended in Jun. 2026 was 23.08%.
Renhe Pharmacy Co (SZSE:000650) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Renhe Pharmacy Co EBITDA Margin % Related Terms
Renhe Pharmacy Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Renhe Pharmacy Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Renhe Pharmacy Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Renhe Pharmacy Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Renhe Pharmacy Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Renhe Pharmacy Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Renhe Pharmacy Co (SZSE:000650) has a EBITDA Margin % of 23.08% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Renhe Pharmacy Co and its competitors. This is 11% above median its historical median of 20.74. Over the past decade, Renhe Pharmacy Co's EBITDA Margin % has ranged from 17.13 to 22.73. According to the industry distribution chart, Renhe Pharmacy Co ranks #335 out of 959 companies in the Drug Manufacturers industry, placing it in the top 34.9%.
Is Renhe Pharmacy Co's EBITDA Margin % too high?
Renhe Pharmacy Co's current EBITDA Margin % of 23.08% is 11% above median its 10-year median of 20.74. Over the past 10 years, this metric has ranged from a low of 17.13 to a high of 22.73. The Drug Manufacturers industry median EBITDA Margin % is 11.89. Renhe Pharmacy Co's value of 23.08% is 94.1% above this industry median. Based on the distribution chart, Renhe Pharmacy Co ranks #335 out of 959 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Renhe Pharmacy Co has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Renhe Pharmacy Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Renhe Pharmacy Co ranks #335 out of 959 companies for EBITDA Margin %. This puts Renhe Pharmacy Co in the upper half of its industry. The industry median EBITDA Margin % is 11.89. Renhe Pharmacy Co's value of 23.08% is 94.1% above this benchmark. Historically, Renhe Pharmacy Co's own EBITDA Margin % has ranged from 17.13 to 22.73 over the past decade. While the company's 10-year median is 20.74 vs. the industry median of 11.89, Renhe Pharmacy Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 11.89, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Renhe Pharmacy Co's current EBITDA Margin % of 23.08% is 94.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Renhe Pharmacy Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 11.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Renhe Pharmacy Co's current EBITDA Margin % is 23.08%, which is 11% above median its own 10-year median of 20.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renhe Pharmacy Co stock overvalued right now?
Based on GuruFocus' analysis, Renhe Pharmacy Co (SZSE:000650) is currently considered Fairly Valued. The stock's GF Value™ is ¥5.07, compared to a current price of ¥5.37 — trading 5.9% above its estimated fair value. The current EBITDA Margin % is 23.08%, which is 11% above median its 10-year median of 20.74 and 94.1% above the Drug Manufacturers industry median of 11.89. Renhe Pharmacy Co's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Renhe Pharmacy Co (SZSE:000650), the current EBITDA Margin % is 23.08% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Renhe Pharmacy Co (SZSE:000650) Overvalued in 2026?
Based on GuruFocus' analysis, Renhe Pharmacy Co stock appears to be overvalued.
The current stock price of ¥5.37 is trading 5.9% above its estimated GF Value™ of ¥5.07.
GuruFocus considers Renhe Pharmacy Co to be Fairly Valued.
Key valuation signals for SZSE:000650:
EBITDA Margin %: 23.08% (11% above median its 10-year median of 20.74)
GF Value™: ¥5.07 vs. price of ¥5.37 (5.9% above fair value)
Industry Position: 94.1% above the Drug Manufacturers median (#335 of 959)
No single metric tells the full story. See the SZSE:000650 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Renhe Pharmacy Co Ltd is a China-based company engaged in the production and sale of Chinese and Western medicines, raw materials, and health-related products, including oral solid dosage forms, oral liquid dosage forms, large-volume injections, small-volume injections, external washes, liniments, suppositories, ointments, and other dosage forms of pharmaceuticals and health-related products. The company's main products include: Renhe Kelike, Youkadan series, Fuyanjie series, Da Huo Luo capsules, Shanliang eye drops, Qinghuo capsules, and Zhengwei capsules.
83GF Score
Get the complete analysis for SZSE:000650
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:000650 has been successfully added to your 
